LEQVIO is a Subcutaneous Injection, Solution in the Human Prescription Drug category. It is labeled and distributed by Novartis Pharmaceuticals Corporation. The primary component is Inclisiran Sodium.
Product ID | 0078-1000_171e003a-8f8e-402e-b79c-fbca7d057373 |
NDC | 0078-1000 |
Product Type | Human Prescription Drug |
Proprietary Name | LEQVIO |
Generic Name | Inclisiran |
Dosage Form | Injection, Solution |
Route of Administration | SUBCUTANEOUS |
Marketing Start Date | 2021-12-22 |
Marketing Category | NDA / |
Application Number | NDA214012 |
Labeler Name | Novartis Pharmaceuticals Corporation |
Substance Name | INCLISIRAN SODIUM |
Active Ingredient Strength | 284 mg/1.5mL |
NDC Exclude Flag | N |
Listing Certified Through | 2023-12-31 |
Marketing Start Date | 2021-12-22 |
NDC Exclude Flag | N |
Sample Package? | N |
Mark Image Registration | Serial | Company Trademark Application Date |
---|---|
LEQVIO 79238111 5640111 Live/Registered |
NOVARTIS AG 2018-05-30 |
LEQVIO 79157840 4741480 Dead/Cancelled |
NOVARTIS AG 2014-11-11 |